CRH plc (NYSE: CRH), a Fortune 500 company and global leader in the building materials industry, has acquired Inwesco Incorporated ("Inwesco"). Inwesco designs, engineers, and manufactures steel, aluminum, and stainless-steel products for overhead and underground distribution systems in the electrical, telecommunications and wastewater industries. The transaction enables meaningful synergies and new opportunities for both companies in the rapidly growing infrastructure products market. 

Owned by the Morris Family since 1999, Inwesco has grown its engineering capabilities and product offering as well as geographic presence by adding locations in Southern California and Texas. Inwesco and the Morris Family desired a partner who could provide resources for future growth, a stable foundation for employees and liquidity for shareholders. Salem Partners built a relationship with Dave and Lisa Morris over multiple years and delivered the ideal transaction to accomplish these goals...(read more). 

Salem Partners, LLC (“Salem”) is pleased to announce a successful closing of a $130 million acquisition of a brand new 1.1 million square foot, mission critical industrial and distribution facility (the “Property”) 100% leased to Ford Motor Company (“Ford”) in suburban Detroit, MI.

The acquisition closed in April of 2022 between a net-lease focused REIT and the original Property developer. The Property serves as one of the main logistics nodes for Ford’s parts division for North America and was a build-to-suit development by the original developer...(read more)​​

OncoNano Medicine, Inc. today announced positive results from a preclinical study of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate the efficacy and tolerability of ONM-501 in animal models for multiple tumor types. ONM-501 is formulated with the core OncoNano OMNITM polymer technology consisting of STING-activating pH-sensitive micelles loaded with an endogenous agonist...(read more). 

OncoNano Medicine, Inc. today announced positive results from the company’s ON-BOARD™ pH-sensitive nanoparticle platform. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate that the clinically validated ON-BOARD™ platform has the potential to be a universal tool for tumor-specific activation and the efficient delivery of proteins for an improved therapeutic index.

“Our ON-BOARD micelle platform is designed to efficiently carry a broad range of payloads to the tumor microenvironment. Capable of being tuned to deliver either small molecules or biologics, the ON-BOARD platform has the potential to be a universal tool for targeted delivery of therapeutics to a range of cancers,” said Tian Zhao, Ph.D., Vice President of Research & Development for OncoNano Medicine, Inc...(read more). 

Salem Partners, LLC (“Salem”) is pleased to announce a successful closing of a $50 million programmatic equity joint venture on November 19th, 2021. The joint venture was structured between Salem’s client, Guardian Yards (“Guardian” or the “Company”) and a West Coast / Los Angeles based private equity firm focused on opportunistic commercial real estate investing. The goal of the joint venture will be to acquire land sites to develop high-performing Industrial Outdoor Storage (“IOS”) | Industrial Service Facilities (“ISF”) real estate properties across the major California markets....(read more)​

​OncoNano Medicine, Inc. today announced a poster presentation at The American Association for Cancer Research (AACR) Virtual Conference on Tumor Immunology and Immunotherapy to be held on October 5-6, 2021. 

The development of ONM-501 represents a new concept in STING activation that could overcome the challenges observed with earlier STING agonists. ONM-501 encapsulates the endogenous STING agonist cGAMP with a proprietary micelle that induces polyvalent STING condensation and prolongs innate immune activation to offer dual ‘burst’ and ‘sustained’ STING activation for a potential highly effective immunotherapy against cancer...(read more)​

OncoNano Medicine, Inc. today announced an oral presentation at The World Molecular Imaging Congress 2021 (WMIC) to be held virtually on October 6-9, 2021.

​OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and a platform of immune-oncology therapeutics that activate and guide the body’s immune system to target cancer...(read more)

​Salem Partners, LLC (“Salem”) is pleased to announce a successful closed transaction on August 25th, 2021, on behalf of its client, Delta Financial, LLC (“Delta”).

Delta hired Salem to find an institutional capital partner for its equipment leasing originations, servicing, and asset management business.
​
Led and founded by two equipment leasing experts (Dave Riggleman and Adam Woodard), Delta is a specialty finance / equipment leasing company that provides financial solutions to Fortune 500 companies looking to lease mission critical equipment such as forklifts, IT infrastructure (servers, etc.), medical equipment and other corporate office, logistics, and manufacturing equipment...(read more). 

Salem Partners, LLC (“Salem”) is pleased to announce a successful, $65 million loan financing that closed on July 23rd, 2021, on behalf of a best-in-class, private equity owned, residential platform (the “Company”).

The Company hired Salem to structure a bespoke credit product against a portfolio of built, under construction, and to-be-built multifamily assets (the “Portfolio”) which will provide the Company with the necessary capital to allocate to its ground-up development pipeline...(read more)

Onconano Medicine Inc. raised around $50 million in series B financing to accelerate the momentum of its technology designed to diagnose and treat cancer with high specificity. The biotech company’s nanosensor works by reacting to low pH and illuminates cancer like a lightbulb, distinguishing cancerous tissue from healthy tissue. This is intended to make it easier for surgeons to remove cancer cells while leaving healthy, functional tissue intact.

The company’s product candidates exploit pH as a biomarker to help patients across the continuum of cancer care, from diagnosis to treatment, and have been gaining momentum in recent years. They include solid tumor therapeutics, agents for real-time image-guided surgery, as well as a platform of product candidates that activate and guide the immune system to target cancer...(read more)

OncoNano Medicine, Inc. today announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross-border institutional investment fund. Proceeds of the financing will be used, in part, to support the Phase 3 clinical trials in the U.S. and Europe for pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors, and accelerate the advancement of the company’s first therapeutic development program, ONM-501, a novel immune-therapeutic formulated with the company’s core delivery technology...(read more)

Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas, today announced the pricing of its initial public offering of 2,650,000 shares of its common stock at a public price of $13.00 per share. The gross proceeds to Femasys from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $34.45 million. All of the shares are being offered by Femasys. In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Capital Market on June 18, 2021, under the ticker symbol “FEMY.” The offering is expected to close on June 22, 2021, subject to customary closing conditions...(read more)

Salem Partners, LLC (“Salem”) is pleased to announce a successful transaction closing on May 12th , 2021, on behalf of its client, Rainmaker Holdings Group LLC (“Rainmaker”).

​Rainmaker hired Salem to find an institutional capital partner for its growing professional athlete / sports lending business. Rainmaker is a specialty finance company that invests structured debt and equity capital in the media & entertainment, real estate, and sports sectors. Rainmaker was looking to significantly grow their lending business to NFL, NBA, MLB, and NHL athletes through a partnership with...(read more) 

Salem Partners, LLC (“Salem”) is pleased to announce a successful transaction closing on May 6th, 2021, on behalf of its client, Jupiter Land Holdings LLC (“Jupiter”).
​
Jupiter hired Salem to identify and raise $30 million in joint-venture LP equity capital (the “Venture”). After closing, the Venture will horizontally develop the raw land into both residential / for-sale lots and commercial pads (industrial) on a 52-acre land parcel in Murrieta, CA. The land site is adjacent to the prestigious Loma Linda University Medical Center, which is one of the...(read more)

​Hubbell Incorporated, (NYSE: HUBB) $8.62B, manufacturer of electronic, industrial, and utility products to solve business challenges, has acquired Armorcast Products Company (“Armorcast”). In coming together, Armorcast’s strong customer base and diverse product line helps Hubbell’s west coast expansion and entry into new market opportunities.
​
Salem Partners has enjoyed a long-standing relationship with the Boghossian family, 2nd generation owners of Armorcast. Following a decade of strong growth, Armorcast engaged Salem Partners in mid-2020 as exclusive sell-side financial advisor.

Salem Partners orchestrated a competitive bidding process that included strategic and private equity buyers. Salem worked alongside Armorcast throughout the transaction on due diligence follow up, buyer negotiations, and company integration...(read more)

Salem Partners, LLC (“Salem”) is pleased to announce a successful closing on behalf of its client, Geyser Holdings, LLC and its CEO, Russell Geyser (“Geyser”). Geyser hired Salem to identify and raise the required joint-venture equity capital with the objective to acquire an institutional class, creative office asset called Hollywood 959, located in the heart of the Hollywood Media District in Los Angeles, CA.

​Hollywood 959 is a recently developed, 250,000 SF class A, creative office campus developed by JH Snyder Co. Located next door to Sunset Las Palmas Studios, Hollywood 959 is... (read more)

​LOS ANGELES, CA August 10, 2020 - Erik Ridgley, CFA is CEO & chief investment officer of Salem Partners Wealth Management, a boutique multi-family investment office for founders, CEOs, entrepreneurial families, and ultra-high net worth individuals. His firm is a fiduciary and fee-only SEC-registered investment adviser (RIA) that combines institutional expertise in public markets and private investments with personalized financial planning and customized portfolios to drive successful after-tax results and build long-term client relationships. This is his fourth decade of investment management...(read more) 

 OncoNano Medicine, Inc., a biotechnology company developing ultra pH-sensitive micelles for the detection, staging and treatment of cancer, today announced two poster presentations – including a late-breaking abstract – for the Society for the Immunotherapy of Cancer (SITC) Annual Meeting to be held in National Harbor, Maryland, November 6-10. OncoNano’s core technology is a library of tunable, ultra pH-sensitive micelles that exist intact under baseline physiological pH conditions but dissociate to release their payload under different, predesignated pH levels... (read more)

OncoNano Medicine, Inc. today announced that it has been awarded $15.4 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates. In ONM-500, OncoNano leverages its proprietary pH-sensitive micelle technology to deliver antigens while activating innate immunity for the treatment of cancers caused by the human papilloma virus (HPV). This grant award adds to an initial $6 million grant that the company received from CPRIT in 2014 for advancement of the company’s ONM-100, where OncoNano’s micelle technology is being used to intraoperatively image tumors during surgical resection, currently in Phase 2 clinical trials... (read more)

Salem Partners, LLC (“Salem Partners”) is pleased to announce the successful completion of a $35 million senior loan for its client, Urban Mining Company (“UMC”) and its investors and affiliates. UMC presented Salem Partners with the challenge to structure a credit product that would provide enough proceeds to refinance its existing real estate debt, finish its mission critical manufacturing facility in the Austin / San Marcos region of Texas and capitalize all transaction and interest costs (a proceeds level which was unavailable by typical bank lenders) all within a tight time frame... (read more)

LOS ANGELES, CA August 6, 2019 - Erik Ridgley, CFA is CEO & Chief Investment Officer of Salem Partners Wealth Management, a boutique multi-family investment office for founders, CEOs, entrepreneurial families, and ultra-high net worth individuals. His firm is a fiduciary and fee-only SEC-registered investment adviser that combines institutional expertise in public markets and private investments with personalized financial planning and customized portfolios to drive successful outcomes and build long-term client relationships...(read more) ​